Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
$1.16
+0.9%
$21.77
$0.51
$10.55
$8.61M0.933.15 million shs39,709 shs
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$10.10
+0.7%
$10.58
$3.52
$23.40
$468.19M0.821.98 million shs758,397 shs
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
$0.47
$0.37
$0.80
$1.82
$4.26M2.034,760 shs9,500 shs
XTLB
XTL Biopharmaceuticals
$1.41
+24.3%
$3.99
$0.86
$3.05
$7.19M1.0523,900 shsN/A
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
0.00%-0.85%-13.81%+8.41%+19.90%
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
0.00%-9.46%-23.41%+11.42%+109.01%
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
0.00%+13.74%+12.04%-2.58%+18.95%
XTLB
XTL Biopharmaceuticals
0.00%+14.23%+22.71%+13.31%-36.43%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
3.3446 of 5 stars
4.63.00.00.02.00.80.6
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
XTLB
XTL Biopharmaceuticals
0.1915 of 5 stars
0.03.00.00.00.01.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
0.00
N/AN/AN/A
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
3.11
Buy$32.22219.19% Upside
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
0.00
N/AN/AN/A
XTLB
XTL Biopharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest XTLB, ICOTF, ANCN, and CAPR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$20.00
6/26/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
6/25/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/25/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $29.00
6/24/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$77.00
6/23/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$43.00 ➝ $22.00
6/17/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00
6/13/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$77.00
5/20/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$31.00
5/14/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/AN/AN/AN/A$2.01 per shareN/A
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$22.27M20.71N/AN/A$3.20 per share3.15
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
XTLB
XTL Biopharmaceuticals
$450K17.02N/AN/A$1.00 per share1.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
-$27.12M-$3.467.73N/AN/AN/A36.08%27.40%N/A
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
-$40.47M-$1.42N/AN/AN/A-181.71%-62.42%-48.36%8/6/2025 (Estimated)
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
-$1.11M-$0.40N/AN/AN/AN/A-288.85%N/A
XTLB
XTL Biopharmaceuticals
-$1.03MN/A0.00N/AN/AN/AN/AN/A

Latest XTLB, ICOTF, ANCN, and CAPR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
-$0.33-$0.53-$0.20-$0.53$3.16 million$2.73 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/AN/AN/AN/AN/A
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
N/AN/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/AN/A
XTLB
XTL Biopharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/A
3.25
3.25
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
N/A
6.55
6.55
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A
0.72
0.72
XTLB
XTL Biopharmaceuticals
N/A
0.61
0.61

Institutional Ownership

CompanyInstitutional Ownership
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
9.05%
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
21.68%
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A
XTLB
XTL Biopharmaceuticals
4.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
167.42 millionN/ANot Optionable
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
10145.68 million40.88 millionOptionable
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A9.05 millionN/ANot Optionable
XTLB
XTL Biopharmaceuticals
N/A5.45 million3.87 millionNot Optionable

Recent News About These Companies

XTL Biopharmaceuticals Ltd. (XTLB) - Yahoo Finance
XTL Biopharmaceuticals names Noam Band as CEO
XTL Biopharmaceuticals Appoints Noam Band as CEO
XTL Biopharmaceuticals Ltd (XTLB)
XTL Biopharmaceuticals Ltd XTLB
XTL Biopharmaceuticals acquires AI firm Social Proxy
XTL Biopharmaceuticals Ltd. (XTLB.TA)
XTL Biopharmaceuticals Ltd. ADR
Dow Surges 350 Points; Fed Holds Rates Steady
Crude Oil Surges 2%; Signet Jewelers Shares Spike Higher
XTL To Aquire The Social Proxy

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anchiano Therapeutics stock logo

Anchiano Therapeutics NASDAQ:ANCN

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Capricor Therapeutics stock logo

Capricor Therapeutics NASDAQ:CAPR

$10.10 +0.08 (+0.75%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$10.12 +0.02 (+0.25%)
As of 07/3/2025 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

iCo Therapeutics stock logo

iCo Therapeutics OTCMKTS:ICOTF

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.

XTL Biopharmaceuticals NASDAQ:XTLB

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.